Trimodal therapy in T2‐4aN0M0 bladder cancer––How to select the best candidate?
Abstract The reported results of trimodal treatment (TMT) in muscle‐invasive bladder cancer vary widely. We attempted to characterize the profile of ideal candidates for this approach. Between 2000 and 2019, 105 patients (median age 78 years) with T2‐4aN0M0 bladder cancer were treated with TMT and a...
Main Authors: | Ofer N. Gofrit, Amichay Meirovitz, Stephen Frank, Igal Rabinovich, Hemda Luwisch, Vladimir Yutkin, Tzahi Neuman, Guy Hidas, Mordechai Duvdevani, Marc Wygoda |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-11-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.3478 |
Similar Items
-
Trimodal electroencephalogram during isoflurane anaesthesia
by: Lorenzo Dimpel
Published: (2016-04-01) -
Differences in Cancer-Specific Mortality after Trimodal Therapy for T2N0M0 Bladder Cancer according to Histological Subtype
by: Francesco Barletta, et al.
Published: (2022-11-01) -
Trimodality therapy for bladder-preservation in the elderly population with invasive bladder cancer
by: Luis eSouhami, et al.
Published: (2014-08-01) -
Trimodal therapy versus radical cystectomy for cT2N0M0 urothelial muscle-invasive bladder cancer: Single-center experience
by: Moayid Fallatah, et al.
Published: (2023-01-01) -
Comparing trimodal therapy with radical cystectomy in muscle-invasive bladder cancer: an updated meta-analysis
by: Ahmad R. Al-Qudimat, et al.
Published: (2023-12-01)